Bristol-Myers Squibb Company
Monthly Stock Prices Chart
This stock price chart for Bristol-Myers Squibb Company, symbol BMY, New York Stock Exchange is updated
monthly. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes.
[Add symbol to "MyMenu"]
Daily and Weekly charts are also available for Bristol-Myers Squibb Company.
Most Recent HeadlinesBIZ: Mar 28th, 2024, 16:05Length: 14972 Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BIZ: Mar 28th, 2024, 16:01Length: 19312 Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease
BIZ: Mar 25th, 2024, 08:00Length: 36820 Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BIZ: Mar 20th, 2024, 16:45Length: 25801 Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BIZ: Mar 20th, 2024, 06:59Length: 57556 Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
BIZ: Mar 19th, 2024, 06:59Length: 16614 Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in "SO, Have You Found It?" Campaign
BIZ: Mar 18th, 2024, 08:44Length: 11291 Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
BIZ: Mar 15th, 2024, 18:27Length: 25318 FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
BIZ: Mar 14th, 2024, 21:35Length: 28797 U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
|